Contact Us |
Using information from our outcomes database, CIBMTR annually prepares and distributes charts summarizing current uses and outcomes of allogeneic and autologous hematopoietic cell transplantation (HCT) in a set of US Summary Slides.
The US Summary Slides are an annual report on data submitted to the CIBMTR by centers in the US and describes information related to practices and general survival outcomes after hematopoietic cell transplantation. The current edition includes transplants performed prior to 2020.
Return to top
Phelan, R., Arora, M., Chen, M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020.
Return to top
Slides are also available upon request by contacting
Charts on slides 2, 3, 4 are estimates based on data reported to CIBMTR, adjusted according to transplant type. These adjustments come from comparisons with other national and international databases.
Acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL) have disease status at HCT classified as CR1, CR2 and relapse/ never in CR.
Myelodysplastic syndrome (MDS) is divided into:
Low risk (refractory anemia [RA] or refractory anemia with ringed sideroblasts [RARS], refractory cytopenia with unilineage dysplasia [RCUD], refractory cytopenia with multilineage dysplasia [RCMD], MDS with isolated del(5q)).
High risk (refractory anemia with excess blasts [RAEB] or chronic myelomonocytic leukemia [CMML]) disease).
Myeloproliferative neoplasms (MPNs) include myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myelomonocytic leukemia, chronic myeloproliferative disease-unclassifiable, chronic neutrophilic leukemia, chronic eosinophilic leukemia and MPN-not otherwise specified.
Chronic myelogenous leukemia (CML) have disease stage classified as hematologic CR, chronic phase, accelerated phase or blast crisis
Lymphoma is classified according to sensitivity to prior chemotherapy (chemosensitive or chemoresistant).
The classification of conditioning regimen intensity is based on the agents, doses and schedules used. Several classification systems are available, and for this report we used a composite classification. Cases defined as reduced-intensity by the transplant center were classified as such. Cases without such information and with available data on chemotherapy agents, radiation and doses, were classified according to the CIBMTR operational definition of conditioning regimen intensity:
Myeloablative conditioning: regimens with total body irradiation doses of ≥500 cGY, single fractionated doses of ≥800 cGY, busulfan doses of >9mg/kg oral or Bu >= 7.2 mg/kg IV, or melphalan doses of >150 mg/m2 given as single agents or in combination with other drugs.
Reduced-intensity conditioning: regimens with lower doses of total body irradiation, fractionated radiation therapy, busulfan, and melphalan than those used to define a myeloablative conditioning regimen (above).